Prasugrel Hydrochloride

盐酸普拉格雷

Report date: 2026/02/28 20:00:37
NME

Base Information

Drug NamePrasugrel Hydrochloride
Drug Alias Name普拉格雷盐酸盐prasugrelum普拉格雷EffientEfient +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPurinergic receptor P2Y12 antagonists
TargetsPurinergic receptor P2Y12
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Ischemic StrokeTibial Fractures +[19] 
Global Approved IndicationsIschemic StrokeThrombosisST Elevation Myocardial Infarction +[10] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2009/02/24
Country/TerritoryCzechiaBelgiumBulgaria +[62] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesDaiichi Sankyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChongqing Pharmaceutical (Group) Co LtdDaiichi Sankyo IncDaiichi Sankyo Co Ltd +[5] 
Inactive CompaniesBoston Scientific CorpDavid Vivas Physician PcAzienda Ospedaliera Universitaria Integrata Verona +[9] 
Active IndicationsIschemic StrokeThrombosisST Elevation Myocardial Infarction +[11] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Tibial FracturesDiabetes Mellitus +[8] 

Other Information

ATC CodeB01AC22
Related LinksWikipediaDrugBankKEGG